Objectives: This study investigated the utility of temporal subtraction computed tomography (TSCT) obtained with temporal bone high-resolution computed tomography (HRCT) for the preoperative prediction of mastoid extension of middle ear cholesteatomas.
Methods: Twenty-eight consecutive patients with surgically proven middle ear cholesteatomas were retrospectively evaluated. The presence of black color in the mastoid region on TSCT suggested progressive changes caused by bone erosion. Enlarged width of the anterior part of mastoid on HRCT was interpreted as suggestive of mastoid extension. Fisher's exact test was used to compare the widths and black color on TSCT for cases with and without mastoid extension. The diagnostic accuracy of TSCT and HRCT for detecting mastoid extension and interobserver agreement during the evaluation of black color on TSCT were calculated.
Results: There were 15 cases of surgically proven mastoid extension and 13 cases without mastoid extension. Patients with black color on TSCT were significantly more likely to have a mastoid extension (p < 0.001). The sensitivity and specificity of TSCT were 0.93 and 1.00, respectively. Patients in whom the width of the anterior part of the mastoid was enlarged were significantly more likely to have a mastoid extension (p = 0.007). The sensitivity and specificity of HRCT to detect the width of the anterior part of the mastoid were 0.80 and 0.77, respectively. Interobserver agreement during the evaluation of TSCT findings was good (k = 0.71).
Conclusions: This novel TSCT technique and preoperative evaluations are useful for assessing mastoid extension of middle ear cholesteatomas and making treatment decisions.
Key Points: •TSCT shows a clear black color in the mastoid region when the middle ear cholesteatoma is accompanied by mastoid extension. •TSCT obtained with preoperative serial HRCT of the temporal bone is useful for assessing mastoid extension of middle ear cholesteatomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-021-08453-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CP ANGLE MEDULLOBLASTOMA WITH SUPRATENTORIAL DROP METS.
J Ayub Med Coll Abbottabad
November 2024
Akbar Niazi Teaching Hospital, IMDC, Islamabad.
Article Synopsis
- * A 17-year-old male presented with headaches and walking difficulties, leading to the discovery of a CPA lesion, which was surgically removed and diagnosed as medulloblastoma; he then received chemo-radiotherapy.
- * After two years, the patient experienced new headaches and seizures, resulting in the identification of a metastatic tumor in the temporal lobe, also confirmed as medulloblastoma.
Comparison of current staging systems for predicting pediatric cholesteatoma outcomes.
Int J Pediatr Otorhinolaryngol
December 2024
Department of Otolaryngology, University of Minnesota, Minneapolis, MN, USA; HealthPartners Medical Group, St. Paul, MN, USA. Electronic address:
Article Synopsis
- This study evaluates the effectiveness of two staging systems (EAONO-JOS and Potsic) in predicting recurrence of cholesteatoma in children with different types (congenital, primary acquired, and secondary acquired).
- Conducted from 2015 to 2023, the research analyzed surgical outcomes from 31 ears in 30 pediatric patients, examining variables like residual disease and factors like stapes erosion that might signal recidivism.
- Results indicated high rates of residual disease, particularly in congenital and primary acquired cases, and found a potential correlation between certain variables and poorer outcomes; however, limitations in the staging systems decreased the predictivity for residual disease.
Myoepithelial Carcinoma of the External Auditory Canal With Extension Into the Middle Ear and Mastoid.
J Craniofac Surg
October 2024
Department of Otolaryngology-Head and Neck Surgery, Southwest Ohio ENT, Dayton, OH.
Myoepithelial carcinoma is a rare disease of the head and neck, with only a handful of cases reported occurring within the external auditory canal, middle ear, and mastoid. The patient discussed is a 67-year-old male with a prior history of a bilateral tympanomastoidectomy for cholesteatoma and a prior history of left parotidectomy and adjuvant radiation for pleomorphic sarcoma. Three years after the parotidectomy, the patient presented with contralateral ear fullness.
View Article and Find Full Text PDFDoes the ChOLE classification relate to the duration of surgery?
Eur Arch Otorhinolaryngol
October 2024
Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, 50924, Cologne, Germany.
Introduction: Cholesteatoma, a challenging entity in otologic surgery, necessitates a standardized classification system for effective communication among healthcare providers and consistent reporting of surgical outcomes. The ChOLE Classification System, introduced by Linder et al., stages cholesteatoma based on extension (Ch), ossicular chain status (O), life-threatening complications (L), and Eustachian tube function and mastoid pneumatization (E).
View Article and Find Full Text PDFExclusive endoscopic tympanoplasty efficacy in the treatment of cholesteatoma without mastoid involvement.
Eur Arch Otorhinolaryngol
November 2024
University of Verona, Via dell'Artigliere 8, Verona, 37129, Italy.
Purpose: The purpose of this study is to determine the recurrence rate of cholesteatoma in patients who have undergone exclusive endoscopic tympanoplasty at our tertiary referral institution. A secondary objective is to analyze different clinical aspects that could be considered risk factors for recurrence to establish if it is possible to determine when a second-look procedure is indicated instead of a clinical follow-up.
Methods: A retrospective study was performed on patients who had undergone exclusive endoscopic tympanoplasty for cholesteatoma in the last eight years and who were followed up for at least one year.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!